Current Report Filing (8-k)
26 5월 2021 - 11:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 26, 2021 (May 14, 2021)
LUCKWEL
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
125
Cambridge Park Drive, Suite 301,Cambridge
|
|
MA
02140
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, include area code +1 (617) 430 5222
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Section
1 - Registrant’s Business and Operations
Item
1.01. Entry Into a Material Definitive Agreement.
On
May 14, 2021, Luckwel Pharmaceuticals Inc. (the “Company”) entered a Subscription Agreement with Bounty Company Limited,
a company incorporated in the British Virgin Islands (the “Investor”), pursuant to which the Company, in a private
placement, agreed to issue and sell to the Investor an aggregate of 187,500 restricted shares of the Company’s common stock,
par value $0.01 per share (the “Common Stock”) at a price per share of $0.40 for gross proceeds of approximately $75,000
(the “Private Placement”). The Private Placement is expected to close on or around May 29, 2021.
The
representations, warranties and covenants contained in the Subscription Agreement were made solely for the benefit of the parties
to the Subscription Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Subscription
Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the Subscription
Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be
read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.
The
foregoing description of the Subscription Agreement is qualified in its entirety by reference to the form of Subscription Agreement,
a copy of which are attached hereto as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
Section
3 – Securities and Trading Markets
Item
3.02 Unregistered Sales of Equity Securities
The
information set forth in Item 1.01 hereof is hereby incorporated by reference into this Item 3.02. The issuance of our common
stock pursuant to the Subscription Agreement will be exempt from registration pursuant to the provisions of Section 4(a)(2) of
the Securities Act of 1933 (the “Securities Act”), as amended and Regulation S under the Securities Act for purposes
of the Private Placement of the shares of common stock as such shares have not been offered or sold in the United States or to,
or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act) or persons in the United
States.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
LUCKWEL
PHARMACEUTICALS INC.
|
|
|
Date:
May 26, 2021
|
|
/s/
Kingrich Lee
|
|
Name:
|
Kingrich
Lee
|
|
Title:
|
Chief
Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Luckwel Pharmaceuticals Inc (GM) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Luckwel Pharmaceuticals Inc. News Articles